CORDIS
EU research results

CORDIS

English EN
Novel Biomaterial-based Device for the Treatment of Progressive MS-   - An Integrated Pan- European Approach

Novel Biomaterial-based Device for the Treatment of Progressive MS- - An Integrated Pan- European Approach

Objective

PMSMatTrain is focusing on gaining a comprehensive understanding of the progressive (late degenerative phase) of multiple sclerosis (PMS) from basics to translation, fully supported by 8 beneficiaries (6 research institutions, 2 SMEs). Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. PMSMatTrain’s Joint Research Education and Training programme (JRTP) will provide early stage researchers with high quality research and transferable skills training in intellectual property, leadership skills, innovation, regulatory affairs, entrepreneurship, gender policy, and medical device evaluation, which will ensure that they are immediately employable in industry. The consortium will develop a multi-modal hyaluronan-based medical device designed to release small molecular weight anti-inflammatory molecules (APRIL and sPIF) followed by remyelination and neuroprotective drugs (ibudilast and miconazole). PMSMatTrain will for the first time utilise these functionalised multi-modal biomimetic hyaluronan scaffolds as a tool to investigate cross-talk between signals arising due to chronic neuroinflammation and those leading to demyelination and axonal loss, while identifying molecular mechanisms that facilitate remyelination and neuroprotection in PMS. This approach could yield the first cortex-proximal and directed biomaterials-based disease-modifying therapy for PMS. These scaffolds will be tested in state of the art MS patient induced stem cell-derived oligodendrocyte cultures and organotypic cultures to investigate MS pathophysiology. In vivo responses will be characterised using field-leading MRI and mass spectrophotometry protocols. PMSMatTrain will also generate a clinically-relevant in silico model of drug elusion and dispersal within the CNS. Our industry partners will develop the end-device by providing standardised manufacturing protocols for scaled-up production and commercialisation of the cGMP product.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

NATIONAL UNIVERSITY OF IRELAND GALWAY

Address

University Road
H91 Galway

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 373 421,60

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

SYDDANSK UNIVERSITET

Denmark

EU Contribution

€ 297 522

UNIVERSITE GRENOBLE ALPES

France

EU Contribution

€ 274 802,04

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 505 576,80

UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA

Italy

EU Contribution

€ 261 499,68

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 512 640

CONTIPRO AS

Czechia

EU Contribution

€ 234 871,56

NEOS SURGERY SL

Spain

EU Contribution

€ 501 809,76

Project information

Grant agreement ID: 813263

Status

Ongoing project

  • Start date

    1 May 2019

  • End date

    30 April 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 962 143,44

  • EU contribution

    € 3 962 143,44

Coordinated by:

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland